文献速递皮肤肿瘤

近十年来黑色素瘤生存率显著改善:2011至2019年匈牙利全国性研究

Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-03-18

该研究利用匈牙利国家健康保险基金和中央统计局数据库,回顾性分析2011至2019年22,948例新诊断恶性黑色素瘤患者的生存情况。结果显示,2017至2019年诊断患者死亡风险较2011至2012年诊断患者低20%(HR 0.80,95%CI 0.73-0.89;p<0.0001);年龄标化5年净生存率从2011至2014年的90.6%升至2015至2019年的95.8%。作者认为匈牙利黑色素瘤生存率与西欧国家相似,研究期间5年内死于黑色素瘤的风险降低超过一半(55%)。

要点

  • 2017至2019年诊断患者死亡风险较2011至2012年诊断患者低20%(HR 0.80,95%CI 0.73-0.89)。
  • 年龄标化5年净生存率2011至2014年为90.6%,2015至2019年为95.8%。
  • 5年总生存率为75.40%,女性80.78%,男性69.52%。

核心结论

  • 匈牙利黑色素瘤生存率与西欧国家相似;研究期间5年内死于黑色素瘤的风险降低超过一半(55%),与成功实施宣传活动和现代疗法广泛可及相吻合。

研究设计与样本

  • 全国性回顾性研究,利用匈牙利国家健康保险基金(NHIF)和中央统计局(CSO)数据库,分析2011至2019年匈牙利黑色素瘤生存情况。
  • 共记录22,948例新诊断恶性黑色素瘤病例(男性47.89%,平均年龄60.75岁,标准差±16.39)。
  • 计算粗总生存率、年龄标化5年净生存率以及年龄、性别与生存的关联。

主要发现

  • 5年总生存率为75.40%,女性80.78%,男性69.52%。
  • 2017至2019年诊断患者较2011至2012年诊断患者死亡风险低20%(HR 0.80,95%CI 0.73-0.89;p<0.0001)。
  • 年龄标化5年净生存率2011至2014年为90.6%,2015至2019年为95.8%;女性分别为93.1%和98.4%,男性分别为87.8%和92.7%。
  • 年龄标化5年净生存率最高见于0至39岁年龄组(2015至2019年期间为94.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking. METHODS: This nationwide, retrospective study examined melanoma survival in Hungary between 2011-2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex and survival were calculated. RESULTS: Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). Five-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017-2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011-2012 (HR 0.80, 95% CI 0.73-0.89; p < 0.0001). Age-standardized 5-year net survival rates in 2011-2014 and 2015-2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0-39 age cohort (94.6% in the 2015-2019 period). CONCLUSION: Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Liszkay G, Benedek A, Polgár C, et al. Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019. J Eur Acad Dermatol Venereol. 2023. PMID: 36785988. doi:10.1111/jdv.18960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。